MedPath

Photodynamic Treatment as Part of Oral Healthcare on Persons With Sjögren's Syndrome

Not Applicable
Not yet recruiting
Conditions
Sjogren Syndrome
Xerostomia
Registration Number
NCT06877546
Lead Sponsor
Koite Health Oy
Brief Summary

This thesis study will investigate whether the regular use of antibacterial photodynamic therapy can alleviate dry mouth symptoms in patients with Sjogren's syndrome and thus be a potential addition to regular oral self-care habits that promote and maintain oral health.

Detailed Description

Sjogren's syndrome is a chronic autoimmune disease that has a holistic impact on a patient's health. The most significant consequence in terms of oral health is the destruction of the salivary glands by the autoimmune reaction, leading to salivary gland failure and consequently dry mouth with reduced saliva secretion. Decreased saliva secretion predisposes to a number of oral health problems, and patients with Sjogren's syndrome are therefore at risk for conditions such as caries and periodontitis, an inflammatory periodontal disease. Regular visits to an oral health professional and good oral hygiene and eating habits and habits promote and maintain oral health. Treatments for dry mouth symptoms associated with Sjogren's syndrome aim to relieve oral symptoms by preserving, replacing and stimulating salivary gland secretion in ways that relieve local inflammation.

Regular home-use of specially designed antibacterial photodynamic therapy device in addition to standard oral self-care has been shown to destroy oral disease-causing bacteria in a way that bacteria cannot develop resistance to. In addition, the treatment method also stimulates saliva production through photobiomodulation. The aim of our study is therefore to investigate, by means of a clinical measurement, whether the regular use of the antibacterial photodynamic therapy device as part of oral self-care can have an effect on the amount of stimulated saliva secretion of a patient with Sjogren's syndrome during the ten-week study period. The aim is also to describe, by means of a questionnaire measuring the subjective symptoms of dry mouth, whether the treatment has an effect on the frequency of the typical symptoms of xerostomia.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
16
Inclusion Criteria
  • Adult (minimum 18 years of age) person with Sjogren's syndrome, with dry mouth symptoms but some saliva secretion.
  • Otherwise perceived health good, primary Sjögren's syndrome patient.
  • No need for antibiotic prophylaxis at the time of a limited oral examination.
  • Signed written informed consent.
  • Subject's co-operation allows participation in the study.
Exclusion Criteria
  • Pregnancy and/or breastfeeding.
  • Fungal infection in the mouth
  • Poor oral health, such as caries lesions or advanced periodontitis.
  • Fixed dentures, or orthodontics.
  • No saliva secretion.
  • Bisphosphonate drugs, multiple (more than two) medications in use.
  • Participation in other oral health research at the same time.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Stimulated saliva3 months

Measurement of stimulated saliva is performed at the baseline and study end visits. On both visits, the stimulated saliva is measured twice: before and after the investigational device use.

Stimulated saliva production is measured in a frontal, sitting, or semi-sitting position by having the patient chew a piece of paraffin, for example, for one minute. During this time, the saliva is swallowed. The patient then continues to chew for five minutes, during which time the saliva accumulated in the mouth is drained into a measuring cup.

The volume of stimulated saliva is measured in milliliters. The measurements will be analyzed using quantitive methods.

Secondary Outcome Measures
NameTimeMethod
Subjective dry mouth (xerostomia) follow-up3 months

Xerostomia questionnaire.

Study subjects are asked to fill in a questionnaire at the study end visit to determine the frequency of xerostomia symptoms during the 3-month study period. The questionnaire is designed to ask a set of pre-set questions, which are answered on a 5-point Likert scale (1, not at all true - 5, completely true).

Trial Locations

Locations (1)

Metropolia University of applied sciences

🇫🇮

Helsinki, Finland

© Copyright 2025. All Rights Reserved by MedPath